The Pharmacophore Hypothesis of Novel Inhibitors for Aurora A Kinase

A three-dimensional pharmacophore model was developed from a series of inhibitors of Aurora A kinase to discover new potent anti-cancer agents using the HypoGen module in the Catalyst software. The pharmacophore model was developed based on the structure of 20 currently available inhibitors, which were carefully selected from the literature. The best hypothesis （Hypo 1） was defined by four features： one hydrogen-bond donor and three hy- drophobic points, with the best correlation coefficient of 0.909, the lowest rms deviation of 1.563, and the highest cost difference of 99.075. The Hypo 1 was then validated by a test set consisting of 24 compounds and by a cross-validation of 95% confidence level through randomizing the data using the CatScramble program, which suggested that a predictive pharmacophore model had been successfully obtained.     

伐地那非衍生物的合成和体内活性评价

首次完成了伐地那非衍生物—2-[2-乙氧基-5-(4-乙基-哌嗪-1-磺酰基)-吡啶]-5-甲基-7-丙基-3H-咪唑[5,1-f]-三 嗪-4-酮(1)的合成, 并且对其进行了家兔阴茎勃起的体内实验, 结果表明该化合物无壮阳作用.     

Synthesis and Crystal Structure of (Z)-N-(2-(diethylamino)ethyl)-7-(5-fluoro-2-oxoindolin-3-ylidene)-2-methyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide Methanol Solvate

The crystal structure of a new compound (Z)-N-(2-(diethylamino)ethyl)-7-(5- fluoro-2-oxoindolin-3-ylidene)-2-methyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamidemethanol solvate (C24H29FN4O2CH4O, Mr = 456.55) has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/c with a = 14.560(3), b = 7.3200(2), c = 22.233(4) , β = 101.78(3)°, V = 2319.7(8) 3 , Z = 4, Dc = 1.307 g/cm 3 , F(000) = 976, μ = 0.092 mm -1 , MoKa radiation (λ = 0.71073), R = 0.0604 and wR = 0.1644 for 4262 observed reflections with I > 2 (I). X-ray diffraction analysis reveals that the indole and pyrrole are almost coplanar. Intramolecular C-H···O and N-H···O hydrogen bonds together with π-π interactions are found in the structure.     

纺锤体驱动蛋白抑制剂的设计、合成与生物活性研究

纺锤体驱动蛋白(kinesin spindle protein, KSP/Eg5)作为潜在的肿瘤治疗靶点, 使发现KSP抑制剂成为热点. 设计并合成了4-氧基-β-四氢咔啉衍生物作为新型的KSP抑制剂, 并测定了其对KSP的抑制活性, 均优于阳性对照物. 其中化合物9c抑制KSP的IC50＝0.065 μmol•L－1, 优于阳性对照物Monastro l100多倍. 生物活性研究表明为抗肿瘤药物提供了新结构类型的候选化合物.     

A novel and efficient route to the construction of the 4-oxa-tricyclo[4.3.1.0]decan-2-one scaffold

A short and efficient route to the synthesis of 4-oxa-tricyclo[4.3.1.0]decan-2-one scaffold 12 in good yield is reported. Essential to the synthesis was the implementation of selective protection of the catechol system in xanthone 2 with Ph₂CCl₂ and MOM groups. Subsequently, a biomimetic tandem Claisen/Diels-Alder reaction occurred to produce the desired tricyclic scaffold 11a as a single isomer. A rationalization of the excellent region and stereoselectivity of this transformation was also proposed.     

具有全新机理的DNA旋转酶抑制剂的筛选及抑菌活性

利用具有新机制的抗耐药菌DNA旋转酶抑制剂GSK299423与DNA旋转酶的晶体复合物(PDB code:2XCS)构建基于配体-受体复合物的药效团模型, 诱骗集(Decoy set)验证结果表明该药效团模型具有较强的活性识别能力. 将药效团模型与分子对接相结合用于筛选化合物库, 通过抑菌活性测定, 获得了具有抗多药耐药菌活性的DNA旋转酶抑制剂LTH02.     

人甲状腺旁素1型受体的结构特征

人甲状腺旁素1 型受体(PTH1R)是骨形成相关的B类G蛋白偶联受体, 其底物甲状腺旁腺素(PTH)及类似物具有抗骨质疏松作用. 由于此类受体的三维结构难以进行实验测定, 本文采用同源模建的方法, 完整构建了胞外区、跨膜区及其它相关区域, 并通过对接研究, 阐明复合物的氢键、疏水性相互作用及其与底物的相互作用关系和关键位点. 为进一步设计和发展此类药物提供理论依据.     

藤黄酸氧化类似物的合成及抗肿瘤活性的二维定量构效关系

报道了35,40-二羟基-6-甲氧基-藤黄酸甲酯(1)、9,10-二羟基-6-甲氧基-藤黄酸甲酯(2)和2-去异己烯-2-(2-甲酰基)乙基-6-甲氧基-藤黄酸甲酯(3)的化学合成和抗肿瘤活性. 采用二维定量构效关系方法经计算机模拟与统计分析, 获得定量构效关系方程. 结果显示, 藤黄酸氧化衍生物的极性体积比、零阶价分子连接性指数、总电荷绝对值和体积与抗肿瘤活性间表现出了良好的线性关系.     

RE(NiCoMnTi)5合金不同放电深度下的交流阻抗谱

研究了La(NiCoMnTi)5、Ce(NiCoMnTi)5、Pr(NiCoMnTi)5和Nd(NiCoMnTi)5四种贮氢合金电极在不同放电深度(DOD, depth of discharge)下的交流阻抗谱.结果表明,在金属相α、氧化物相β和α＋β相区,合金有明显不同的放电动力学特征.在50％DOD时,四种合金表面吸附电阻Rsf和法拉第阻抗RF分别与它们的最大放电容量C50,max和高倍率放电率κ呈近似的线性关系,即Rsf和RF越小,C50,max和κ分别越大.     

新型吲哚咔唑化合物的合成与抗肿瘤活性

设计合成了一系列吲哚咔唑结构的抗肿瘤新化合物. 通过对反应溶剂进行选择和调整, 优化了吲哚咔唑母核合成的反应条件, 使后处理更为简便. 用溴化噻唑蓝四氮唑(MTT)法对所合成的9个目标化合物进行了体外细胞毒活性测试, 结果表明, 化合物4a, 4b, 4d, 4f和4i对人结肠癌HCT116和鼠白血病P388细胞的活性均强于阳性对照ED-571, 其中化合物4f对P388细胞的活性是阳性对照的10倍.